|
Vaccine Comparison
human apo B-100 peptide-2 protein vaccine |
MDA-modified human apo B-100 peptide Vaccine |
Vaccine Information |
Vaccine Information |
- Vaccine Name: human apo B-100 peptide-2 protein vaccine
- Vaccine Ontology ID: VO_0004275
- Type: Subunit vaccine
- Status: Research
- Antigen: Peptide-2, a peptide taken from the sequence of human apo B-100, with an amino acid sequence of ATRFKHLRKYTYNYEAESSS (Chyu et al., 2005).
- Adjuvant:
- Preparation: Peptide antigen was prepared using Imject SuperCarrier EDC kit (Pierce, Rockford, IL) according to manufacturer’s instruction with minor modification. One milligram peptide in 500 μl conjugation buffer was mixed with 2 mg carrier in 200 μl deionized water. This mixture was then incubated with 1 mg conjugation reagent (EDC, 1-ethyl-3-[3-dimethylaminopropyl]-carbodiimide HCl) at room temperature for 2 h followed by dialysis against 0.083 M sodium phosphate, 0.9 M sodium chloride, pH 7.2, solution overnight at 4 °C. The dialyzed conjugate was diluted with Imject dry blend purification buffer to a final volume of 1.5 ml. Alum was used as immunoadjuvant and mixed with peptide conjugate with 1:1 dilution in volume. The amount of peptide in each immunization was 33 μg/100 μl per injection (Chyu et al., 2005).
- Immunization Route: subcutaneous injection
|
|
References |
References |
Chyu et al., 2005: Chyu KY, Zhao X, Reyes OS, Babbidge SM, Dimayuga PC, Yano J, Cercek B, Fredrikson GN, Nilsson J, Shah PK. Immunization using an Apo B-100 related epitope reduces atherosclerosis and plaque inflammation in hypercholesterolemic apo E (-/-) mice. Biochemical and biophysical research communications. 2005; 338(4); 1982-1989. [PubMed: 16288717].
|
Fredrikson et al., 2005: Fredrikson GN, Andersson L, Söderberg I, Dimayuga P, Chyu KY, Shah PK, Nilsson J. Atheroprotective immunization with MDA-modified apo B-100 peptide sequences is associated with activation of Th2 specific antibody expression. Autoimmunity. 2005; 38(2); 171-179. [PubMed: 16040338].
|
|